Journal Information
Vol. 21. Issue 4.
Pages 477-480 (July - August 2017)
Share
Share
Download PDF
More article options
Visits
4445
Vol. 21. Issue 4.
Pages 477-480 (July - August 2017)
Brief communication
Open Access
Antimicrobial resistance and plasmid replicons in Yersinia enterocolitica strains isolated in Brazil in 30 years
Visits
4445
Miliane R. Frazão, Leonardo N. Andrade, Ana L.C. Darini, Juliana P. Falcão
Corresponding author
jufalcao@fcfrp.usp.br

Corresponding author.
Universidade de São Paulo (USP), Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Departamento de Análises Clínicas, Toxicológicas e Bromatológicas (DACTB), Ribeirão Preto, SP, Brazil
This item has received

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. General data of the 34 Yersinia enterocolitica strains studied.
Abstract

Some studies evaluated the resistance profile of the Y. enterocolitica strains isolated in diverse countries. However, in Brazil the isolation and the study of Y. enterocolitica are not common and therefore information about the antimicrobial resistance profile of this species in this country is scarce. Therefore, the aim of this study was to evaluate the antimicrobial resistance of Y. enterocolitica of biotypes 1A, 2 and 4 isolated from clinical and non-clinical sources between 1979 and 2012, in Brazil. This study showed that some Yersinia enterocolitica of different biotypes remain susceptible to antimicrobials used for gastroenteritis treatment. Moreover, neither acquired resistance genes nor diversity of plasmids replicons were found; however, variation in the in vitro intrinsic resistant pattern was detected, except the non-resistance to cefoxitin in all strains. Notwithstanding, due to epidemiological link between Y. enterocolitica and the pork production chain, monitoring plasmid acquired resistance in Y. enterocolitica could also be considered for antimicrobial resistance control purposes and food safety measures.

Keywords:
Yersinia enterocolitica
Resistance profile
Plasmid replicon
Full Text

Yersinia enterocolitica is the most prevalent Yersinia species that causes illness in humans and animals. Y. enterocolitica strains can be classified into six biotypes, being biotypes 1B, 2, 3, 4, and 5 associated with illness in humans and animals, while biotype 1A comprises strains that are considered to be primarily nonpathogenic.1

Y. enterocolitica intrinsic resistance to ampicillin, ticarcillin, amoxycillin-clavulanate, cefazolin, and cephalothin has been assigned by the Clinical & Laboratory Standards Institute (CLSI).2 In addition, intrinsic resistance to cefamandole and cefoxitin has also been recognized by EUCAST.3Y. enterocolitica have shown susceptibility in vitro to aminoglycosides, tetracycline, chloramphenicol, extended-spectrum cephalosporins, and trimethoprim-sulfamethoxazole. Resistance to fluoroquinolones has been observed in some countries due to chromosomal mutation mechanism.4 In Brazil, the isolation and the study of Y. enterocolitica are not common and thus information about the antimicrobial resistance of isolates of this species in this country is scarce.5–8

Therefore, the aims of this study were to determine the antimicrobial susceptibility profile and asses the intrinsic resistance pattern, to search for plasmid acquired resistance genes, and to investigate plasmid replicons in Y. enterocolitica isolated in Brazil.

A total of 34 Y. enterocolitica strains biotype 1A (n=2), 2 (n=12), and 4 (n=20) were studied. These strains were selected from the collection of the “Brazilian Reference Center on Yersinia spp. other than Y. pestis” isolated from 1979 to 2012, based on the resistance profiles found for some other strains of the biotypes mentioned above in previous studies of our group.5–7

The antimicrobial susceptibility profile was determined using the disk diffusion method and interpreted according to the breakpoints for Enterobacteriaceae.2,3,9 Moreover, double-disk synergy test (DDST) was performed to detect extended-spectrum beta-lactamase (ESBL) production,10 enzymes able to hydrolyze third- and fourth-generation cephalosporins.

Plasmid acquired genes coding for resistance to extended-spectrum cephalosporins (blaCTX-M, blaTEM and blaSVH), tetracyclines (tet), aminoglicosydes (aac(6′)-Ib), and fluoroquinolones (qnr, aac(6′)-Ib-cr, qepA and oqxAB) were searched.11–14 Moreover, plasmids were searched following the PCR-based replicon typing (PBRT) scheme targeting replicons of the major incompatibility groups (Inc) harboring/disseminating antibiotic resistance genes in Enterobacteriaceae.15

Y. enterocolitica samples showed recognized intrinsic resistance to cefazolin (CFZ) (34/34), cephalotin (CF) (34/34), ampicillin (AMP) and ticarcillin (TIC) (32/34), and amoxicillin-clavulanic acid (AMC) (19/34). This inherent non-susceptibility pattern has been displayed by all or almost all strains from different biotypes and isolation sources. However, cefoxitin (FOX) intrinsic resistance, additionally also recognized by EUCAST,16 was not detected (Table 1).

Table 1.

General data of the 34 Yersinia enterocolitica strains studied.

Strains  Biotype  Source  Year  Resistance profile 
IP 7382a  Animal feces  1979  AMP, TIC, CFZ, CF, NIT 
IP 7884a  Animal feces  1979  AMP, TIC, CFZ, CF 
FCF 57  1A  Milk  1980  AMP, TIC, AMC, CFZ, CF, NIT 
FCF 86  Fresh water  1982  AMP, TIC, AMC, CFZ, CF 
FCF 88  Fresh water  1983  AMP, TIC, AMC, CFZ, CF 
FCF 268  1A  Chicken meat  1984  AMP, TIC, AMC, CFZ, CF 
FCF 90  Fresh water  1984  AMP, TIC, AMC, CFZ, CF 
FCF 376 a  Human feces  1984  AMP, TIC, CFZ, CF 
FCF 93  Fresh water  1985  AMP, TIC, AMC, CFZ, CF 
FCF 94  Fresh water  1986  AMP, TIC, CFZ, CF 
FCF 96  Fresh water  1987  AMP, TIC, CFZ, CF 
FCF 100  Fresh water  1988  AMP, TIC, AMC, CFZ, CF, PTZ 
FCF 418a  Human diarrheic feces  1988  AMP, TIC, CFZ, CF 
FCF 103  Fresh water  1989  AMP, TIC, CFZ, CF 
FCF 105  Fresh water  1990  AMP, TIC, CFZ, CF 
FCF 110  Fresh water  1991  AMP, TIC, AMC, CFZ, CF 
FCF 113  Fresh water  1992  AMP, TIC, CFZ, CF 
FCF 115  Fresh water  1993  AMC, CFZ, CF 
FCF 600a  Human diarrheic feces  1998  AMP, TIC, CFZ, CF, CPM 
FCF 601  Animal feces  1998  AMP, TIC, AMC, CFZ, CF 
FCF 605a  Human diarrheic feces  1999  AMP, TIC, CFZ, CF, NIT 
FCF 606a  Human diarrheic feces  1999  AMP, TIC, AMC, CFZ, CF, NAL, NIT 
FCF 607a  Human diarrheic feces  1999  AMP, TIC, AMC, CFZ, CF, CPM, NIT 
FCF 609a  Human diarrheic feces  2000  AMP, TIC, CFZ, CF, NAL 
FCF 612a  Human diarrheic feces  2000  AMP, TIC, AMC, CFZ, CF 
FCF 613a  Human diarrheic feces  2003  AMP, TIC, CFZ, CF, NAL 
FCF 614a  Human diarrheic feces  2003  AMP, TIC, CFZ, CF, NAL, SXT 
FCF 615a  Human blood  2004  AMP, TIC, AMC, CFZ, CF 
FCF 618a  Human diarrheic feces  2008  AMP, TIC, CFZ, CF, NAL, KAN 
FCF 619a  Human diarrheic feces  2008  AMP, TIC, AMC, CFZ, CF, SXT 
FCF 620a  Human blood  2008  AMC, CFZ, CF 
FCF 624a  Lymph node swab  2010  AMP, TIC, AMC, CFZ, CF, CFX, NAL, NOR, CIP, LEV, TET, DOX, SXT, NIT, FOS 
FCF 625a  Lymph node swab  2010  AMP, TIC, CFZ, CF 
FCF 626a  Human blood  2012  AMP, TIC, AMC, CFZ, CF, NAL 

Bold and underline type means acquired resistance other than plasmid acquired resistance investigated here.

AMP, ampicillin; TIC, ticarcillin; AMC, amoxicillin-clavulanic acid; PTZ, piperacillin-tazobactam; CF, cephalotin; CFZ, cefazolin; CFX, cefuroxime; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; CPM, cefepime; ATM, aztreonam; ERT, ertapenem; GEN, gentamicin; AMI, amikacin; KAN, kanamycin; SXT, trimethoprim-sulfamethoxazole; NAL, nalidixic acid; NOR, norfloxacin; CIP, ciprofloxacin; LEV, levofloxacin; C, chloramphenicol; NIT, nitrofurantoin; TET, tetracycline; DOX, doxycyclin; TGC, tigecycline; PB, polymyxin B; FOS, fosfomycin. All manufactured by Oxoid (Basingstoke, Hampshire, UK).

a

Presence of IncFIIY plasmid replicon.

Most Y. enterocolitica isolates harbored chromosomal genes blaA and blaB encoding for two beta-lactamases, respectively, BlaA (a non-inducible broad-spectrum carbenicillinase) and BlaB (an AmpC-type inducible cephalosporinase).17 The differential expression and activities of these two enzymes determine the differential beta-lactam intrinsic resistance among biotypes of Y. enterocolitica.4 Moreover, a small percentage of strains may appear susceptible due to laboratory method variation, mutation or resistance expression. Therefore, in vitro susceptible results should be viewed with caution because in vivo non-susceptibility could lead to therapeutic failure. Approximately half of the strains (14/34) showed also acquired resistance (Table 1). Beta-lactam resistance to piperacillin-tazobactam (PTZ) and cefuroxime (CFX) could have been due to BlaB (AmpC) overproduction. However, BlaB overproduction does not explain cefepime (CPM) resistance, once AmpC beta-lactamases are not able to hydrolyze fourth-generation cephalosporins (like CPM). Thereby, once ESBL production was not detected and the recognized enzymatic intrinsic resistance is not able to confer this phenotype, other mechanism of resistance like porin loss and/or over expression of efflux system could have been responsible to CPM as well as PTZ and CFX resistance in the isolates studied here.17,18 Nitrofurantoin (NIT) resistance was detected in 17.6% (6/34) of strains; other studies reported 36% resistant19 as well as 100% susceptible strains.20 Trimethoprim-sulfamethoxazole (SXT) resistance was founded in 8.8% (3/34) of strains, and 4%20 to 10%21 of resistance were seen in other studies. Nalidixic acid (NAL) resistance was observed in 20.5% (7/34) of strains and other studies have described an increasing number of strains showing NAL resistance over recent years22 reaching 23%.23 In addition, fluoroquinolones like norfloxacin (NOR), ciprofloxacin (CIP), and levofloxacin (LEV) resistance was found in just one strain named FCF624, corroborating the findings of other studies where rates of fluoroquinolone resistance were significantly lower than those observed for NAL alone.22 Tetracycline (TET), doxycyclin (DOX), kanamycin (KAN), and fosfomycin (FOS) resistance were also detected in the FCF624 strain (Table 1), showing multiple resistance phenotypes, rarely reported in Y. enterocolitica.4

No plasmid acquired genes coding for resistance to extended-spectrum cephalosporins, tetracyclines, aminoglicosydes, and fluoroquinolones were found. Thereby, resistance to these antimicrobial classes could have chromosomal origin.

In this study, just IncFIIY plasmid replicon were detected mostly in strains of the pathogenic biotype 4 isolated from human diarrheic feces; however, it did not relate to any acquired resistance genes (Table 1). IncFII-like plasmids are mostly considered as virulence plasmids, such as pYV harboring type III secretion system (yops), that can be present alone or co-resident and compatible with other FII-positive resistance plasmids (typable by the FII, FIA, FIB, FIC loci) within the same bacterial cell24 (http://pubmlst.org/plasmid/). Plasmids carrying transferable antibiotic resistance genes have been detected from a variety of Enterobacteriaceae25; however reports in Y. enterocolitica are rare,4 such as the conjugative plasmid (30–40kb) transferring chloramphenicol, streptomycin, and sulfonamide resistance phenotypes from a sporadic Y. enterocolitica 4/O:3 strain.26

Y. enterocolitica is a non-hospital pathogen and the absence of acquired resistance genes could be explained by little interaction with hospital pathogens and consequently a reduced possibility to genetic exchanges, such as horizontal gene transfer mediated by plasmids. Nevertheless, resistance genes and resistant bacteria have been alarmingly and increasingly found in food and food-producing animals,27 such as mcr-1 gene in ESBL-producing Escherichia coli strains isolated from pig.28Y. enterocolitica is a zoonotic pathogen that causes gastrointestinal disease and porcine animal seems to be the main carrier of this bacterial species.29 Likewise, the food chain could boost Y. enterocolitica antimicrobial resistance.

In summary, our study showed that some Brazilian Y. enterocolitica strains of different biotypes remain susceptible to drugs used for treating gastroenteritis, as well as extra-intestinal and hospital infections. In addition, variation in the in vitro intrinsic resistant pattern was detected, except non-resistance to FOX in all strains. Moreover, neither acquired resistance genes nor diversity of plasmids replicons searched were found. Notwithstanding, due to epidemiological link between Y. enterocolitica and pork production chain, monitoring plasmid acquired resistance in Y. enterocolitica could also be considered for antimicrobial resistance control purposes and food safety measures.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

We thank Sao Paulo Research Foundation (FAPESP-2012/19132-1) for financial support. During the course of this work, Frazão, M.R. was supported by a scholarship granted by Coordination for the Improvement of the Higher Education Personnel (CAPES). Andrade, L.N. was supported by a postdoctoral fellowship from Programa Nacional de Pós Doutorado (PNPD)/CAPES 2015.

References
[1]
N. Drummond, B.P. Murphy, T. Ringwood, M.B. Prentice, J.F. Buckley, S. Fanning.
Yersinia enterocolitica: a brief review of the issues relating to the zoonotic pathogen, public health challenges, and the pork production chain.
Foodborne Pathog Dis, 9 (2012), pp. 179-189
Epub 2012/01/06
[2]
CLSI.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing.
Clinical Lab Standards Institute, (2016),
M100S (26th edition)
[3]
EUCAST ECoAST. Breakpoint tables for interpretation of MICs and zone diameters 2016; Version 6.0, valid from 2016-01-01.
[4]
A. Fabrega, J. Vila.
Yersinia enterocolitica: pathogenesis, virulence and antimicrobial resistance.
Enferm Infecc Microbiol Clin, 30 (2012), pp. 24-32
Epub 2011/10/25
[5]
J.P. Falcao, M. Brocchi, J.L. Proenca-Modena, G.O. Acrani, E.F. Correa, D.P. Falcao.
Virulence characteristics and epidemiology of Yersinia enterocolitica and Yersiniae other than Y. pseudotuberculosis and Y. pestis isolated from water and sewage.
J Appl Microbiol, 96 (2004), pp. 1230-1236
Epub 2004/05/14
[6]
J.P. Falcao, D.P. Falcao, A. Pitondo-Silva, A.C. Malaspina, M. Brocchi.
Molecular typing and virulence markers of Yersinia enterocolitica strains from human, animal and food origins isolated between 1968 and 2000 in Brazil.
J Med Microbiol, 55 (2006), pp. 1539-1548
Epub 2006/10/13
[7]
F. Campioni, J.P. Falcao.
Genotypic diversity and virulence markers of Yersinia enterocolitica biotype 1A strains isolated from clinical and non-clinical origins.
APMIS, 122 (2014), pp. 215-222
Epub 2013/06/15.
[8]
M.R. Frazao, J.P. Falcao.
Genotypic diversity and pathogenic potential of Yersinia enterocolitica biotype 2 strains isolated in Brazil.
J Appl Microbiol, 118 (2015), pp. 1058-1067
Epub 2015/02/03
[9]
CLSI CaLSI.
Performance standards for antimicrobial disk susceptibility tests.
Clinical and Laboratory Standards Institute, (2016),
M02-A12 (12th edition)
[10]
V. Jarlier, M.H. Nicolas, G. Fournier, A. Philippon.
Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.
Rev Infect Dis, 10 (1988), pp. 867-878
Epub 1988/07/01.
[11]
L.N. Andrade, L.A. Minarini, A. Pitondo-Silva, et al.
Determinants of beta-lactam resistance in meningitis-causing Enterobacteriaceae in Brazil.
Can J Microbiol, 56 (2010), pp. 399-407
[12]
M.D. Tamang, H.M. Nam, M.H. Chae, et al.
Prevalence of plasmid-mediated quinolone resistance determinants among Escherichia coli isolated from food animals in Korea.
Foodborne Pathog Dis, 9 (2012), pp. 1057-1063
[13]
H.B. Kim, M. Wang, C.H. Park, E.C. Kim, G.A. Jacoby, D.C. Hooper.
oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae.
Antimicrob Agents Chemother, 53 (2009), pp. 3582-3584
Epub 2009/06/17
[14]
L.K. Ng, I. Martin, M. Alfa, M. Mulvey.
Multiplex PCR for the detection of tetracycline resistant genes.
Mol Cell Probes, 15 (2001), pp. 209-215
Epub 2001/08/22
[15]
A. Carattoli, A. Bertini, L. Villa, V. Falbo, K.L. Hopkins, E.J. Threlfall.
Identification of plasmids by PCR-based replicon typing.
J Microbiol Methods, 63 (2005), pp. 219-228
[16]
Z.W. Bent, G.M. Young.
Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
Antimicrob Agents Chemother, 54 (2010), pp. 4000-4002
Epub 2010/06/16
[17]
C. Liu, X. Wang, Y. Chen, et al.
Three Yersinia enterocolitica AmpD homologs participate in the multi-step regulation of chromosomal cephalosporinase AmpC.
Front Microbiol, 7 (2016), pp. 1282
Epub 2016/09/03
[18]
G.A. Jacoby.
AmpC beta-lactamases.
Clin Microbiol Rev, 22 (2009), pp. 161-182
[19]
P. Gousia, V. Economou, H. Sakkas, S. Leveidiotou, C. Papadopoulou.
Antimicrobial resistance of major foodborne pathogens from major meat products.
Foodborne Pathog Dis, 8 (2011), pp. 27-38
Epub 2010/11/03
[20]
J.A. Funk, H.F. Troutt, S.A. Davis, C.P. Fossler.
In vitro susceptibility of Yersinia enterocolitica isolated from the oral cavity of swine.
J Food Prot, 63 (2000), pp. 395-399
Epub 2000/03/15
[21]
L.A. Rusak, C.M.F. dos Reis, A.V. Barbosa, et al.
Phenotypic and genotypic analysis of bio-serotypes of Yersinia enterocolitica from various sources in Brazil.
J Infect Dev Countries, 8 (2014), pp. 1533-1540
[22]
A. Fabrega, I. Roca, J. Vila.
Fluoroquinolone and multidrug resistance phenotypes associated with the overexpression of AcrAB and an orthologue of MarA in Yersinia enterocolitica.
Int J Med Microbiol, 300 (2010), pp. 457-463
Epub 2010/06/01
[23]
S. Capilla, J. Ruiz, P. Goni, et al.
Characterization of the molecular mechanisms of quinolone resistance in Yersinia enterocolitica O:3 clinical isolates.
J Antimicrob Chemother, 53 (2004), pp. 1068-1071
Epub 2004/05/01
[24]
L. Villa, A. Garcia-Fernandez, D. Fortini, A. Carattoli.
Replicon sequence typing of IncF plasmids carrying virulence and resistance determinants.
J Antimicrob Chemother, 65 (2010), pp. 2518-2529
Epub 2010/10/12
[25]
A. Carattoli.
Resistance plasmid families in Enterobacteriaceae.
Antimicrob Agents Chemother, 53 (2009), pp. 2227-2238
[26]
L.M. Sihvonen, S. Toivonen, K. Haukka, M. Kuusi, M. Skurnik, A. Siitonen.
Multilocus variable-number tandem-repeat analysis, pulsed-field gel electrophoresis, and antimicrobial susceptibility patterns in discrimination of sporadic and outbreak-related strains of Yersinia enterocolitica.
BMC Microbiol, 11 (2011), pp. 42
Epub 2011/02/26
[27]
E. Liebana, A. Carattoli, T.M. Coque, et al.
Public health risks of enterobacterial isolates producing extended-spectrum beta-lactamases or AmpC beta-lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options.
Clin Infect Dis, 56 (2013), pp. 1030-1037
[28]
A. Brauer, K. Telling, M. Laht, et al.
Plasmid with colistin resistance gene mcr-1 in ESBL-producing Escherichia coli strains isolated from pig slurry in Estonia.
Antimicrob Agents Chemother, (2016),
Epub 2016/08/31
[29]
N. Drummond, R. Stephan, P. Haughton, B.P. Murphy, S. Fanning.
Further characterization of three Yersinia enterocolitica strains with a nalidixic acid-resistant phenotype isolated from humans with diarrhea.
Foodborne Pathog Dis, 10 (2013), pp. 744-746
Epub 2013/06/12

These authors contributed equally to this work.

Copyright © 2017. Sociedade Brasileira de Infectologia
Download PDF
The Brazilian Journal of Infectious Diseases
Article options
Tools